SLC5A2 and chronic kidney disease: Mutruc et al. concluded that SGLT2 inhibitors are the foundation of kidney protection in patients with diabetes and CKD, helping to reduce albuminuria, lower estimated glomerular filtration rate (eGFR) drops, and prevent end-stage kidney disease (ESKD).